Pharmacokinetic-pharmacodynamic modeling of the antihypertensive effect of eprosartan in Black and White hypertensive patients

Clinical Pharmacokinetics
Petra C van Rijn-BikkerRon A A Mathôt


It is well recognized that many antihypertensive drugs exhibit large interindividual variability in effect and that this wide range of patient response to antihypertensive drugs is a major problem in achieving blood pressure (BP) control. Variability in both drug concentration and drug effect may cause the heterogeneity in antihypertensive drug response. However, for most antihypertensive drugs, no clear relationship between drug concentration and its effect on BP has been reported. This study aimed to describe the relationship between eprosartan exposure and its effect on the systolic blood pressure (SBP) using population pharmacokinetic-pharmacodynamic modeling. Interindividual variability in pharmacokinetics and pharmacodynamics was quantified and the influence of covariates on this relationship was evaluated. Eprosartan plasma concentrations and SBP measurements were determined in 86 mildly hypertensive patients from the ROTATE study aged 48.1 ± 7.6 years with different ethnic backgrounds (33 White Dutch, 41 Creole Surinamese, 12 Hindustani Surinamese). In 12 of these patients, pharmacokinetics were densely sampled and 24-h ambulatory BP measurements were obtained. Data were analyzed using nonlinear mixed effects modeling. ...Continue Reading


Nov 1, 1989·British Journal of Clinical Pharmacology·R DonnellyJ L Reid
Oct 1, 1989·British Journal of Clinical Pharmacology·H J GomezE P MacCarthy
Jan 1, 1993·European Journal of Clinical Pharmacology·R DonnellyJ L Reid
Mar 3, 1998·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·P A Meredith
May 23, 1998·Journal of Clinical Pharmacology·M C ChapelskyD K Jorkasky
Oct 9, 1998·British Journal of Clinical Pharmacology·D M TeneroD K Jorkasky
Mar 20, 2002·Cell Biochemistry and Biophysics·P Morsing, G Vauquelin
Feb 7, 2003·Fundamental & Clinical Pharmacology·G VauquelinP M L Vanderheyden
Oct 20, 2004·Annals of Internal Medicine·Lizzy M BrewsterJos Kleijnen
Apr 6, 2007·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Xue-Ning LiChen Yu
Jun 20, 2008·Lancet·Bryan WilliamsPeter Sever
Jul 16, 2008·Molecular and Cellular Endocrinology·I Van Liefde, G Vauquelin
Apr 1, 2009·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·Josep RedonGert van Montfrans
Sep 26, 2009·American Journal of Hypertension·Petra C van Rijn-BikkerRichard P Koopmans
Oct 20, 2009·Journal of Hypertension·Giuseppe ManciaUNKNOWN European Society of Hypertension
Oct 6, 2010·Hypertension·John M FlackUNKNOWN International Society on Hypertension in Blacks
Aug 27, 2011·BMJ : British Medical Journal·Taryn KrauseUNKNOWN Guideline Development Group

❮ Previous
Next ❯


Oct 10, 2018·Annual Review of Pharmacology and Toxicology·Tanima DeMinoli A Perera
Oct 19, 2019·Clinical Pharmacology and Therapeutics·Christine GarnettTzu-Yun McDowell
Mar 1, 2017·Translational and Clinical Pharmacology·Choon Ok KimDong-Seok Yim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.